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ECONOMIC ASPECTS OF INTERMITTENT
CLAUDICATION
Cos t data on the diagnosis or treatment of claudica-
tion appear to be very scarce in the medical and the
economic liter ature. This is partl y because an alyses
of c1audicants ha ve presented resul ts on the global
cost of the d isea se (including all types of patients)
or instead of the Fontaine class ification ha ve us ed
som e other grouping method that renders interp re-
tation of the results difficult. In other cases, the
results concerned small numbers of patients with
minimal description of the sampling methods and
little externa l validity. In the results presented later
in this document and also in Economic Aspects of
Acute Limb Ischaemia and Economic Aspects of
Cr itical Limb Isch aem ia, costs are in US dollars with
the European Euro in brackets, and local currencies
were converted based on th e Organisation for
Economic Cooperation and Development (OECD)
purchasing power parity index. The year of the
study is indicated.
B 5.1.1
Diagnostic Strategies
When assessing diagnostic strategies for patients with
claudication, the economic analysis can focus on (1)
the most effective diagnostic strategy for a given indi-
vidual, (2) the screening strategy for the population at
large, or (3) a subset of those presenting risk factors
(eg, smoking or cardiac disease). The investigations
concern risk factors that could benefit from secondary
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prevention-diseased peripheral arteries and the cir-
culatory system (heart, brain)-to ascertain a diagno-
sis, but more significantly, to plan the most appropri-
ate treatment. In countries where the economic con-
straints have resulted in a limited supply of high-tech-
nology facilities, the optimal use of these facilities is a
major issue. Thus, an investigation may be extremely
cost-effective if it results in ascertaining before an
intervention whether a patient should be operated on.
If not, the benefits of deferring surgery are not only to
the patient but also to another patient, who will bene-
fit from a freed time slot in the operating room. These
opportunity costs are often difficult to estimate.
When diagnosing risk factors in patients with IC,
studies have been concerned with good clinical prac-
tice but seldom with the economic evaluation of the
diagnostic strategies recommended. The cost-effec-
tiveness analyses of screening strategies for hypercho-
lesterolaemia and high blood pressure are relevant
only in relation to the treatment strategies for risk fac-
tors. The interest of screening for cardiovascular risk
factors in a population in which the prevalence of ath-
erosclerosis is high no longer needs to be demonstrat-
ed. There are few data on the cost-effectiveness of
investigating other arterial systems (cardiac and cere-
bral mostly) in patients with claudication.
The actual costs of diagnostic tests for patients with
IC were estimated in the vascular laboratory of a US
hospital.' Costs were estimated from the actual time
spent by. doctors and technicians, equipment amorti-
zation and maintenance, supplies, and overheads. The
authors computed the costs for their own institution
and estimated a national average cost for 1993 derived
from a survey of six academic US centres. The esti-
mated cost of lower-extremity arterial duplex was
$127 to $141 (Euro 118-131). The cost of plethysmog-
raphy (any type) was estimated to be $63 to $70 (Euro
59-65). These costs are highly dependent on the total
number of procedures performed per year; the under-
lying assumption of these cost computations was that
the equipment was operated at a 77% efficiency level,
which represented 988 hours per machine annually.'
B 5.1.2
Cost of Treatment for Intermittent Claudication
A review of controlled clinical trials in patients with
IC (stage II) reported the ambulatory costs of drug
treatment, which had been shown to improve the
pain-free walking distance by at least 30% over
placebo or absence of treatment.2 Costs included the
purchase of the drug and physician fees in 1994. The
duration of treatment varied from 2 to 8 months.
When considering the effects of treatment on pain-
free walking distance, it appeared that supervised
exercise alone has as good a result as most drugs,
but at a $504 cost (Euro 468) per 24 months, includ-
ing physiotherapist fees.
The costs in 1994 ranged from $133 (Euro 124) for
3 months of treatment with oral naftidrofuryl to
$3,220 (Euro 2,995) for 4 weeks' infusion with
alprostadil and are not proportional to therapeutic
efficacy> The variety of treatment duration and the
lack of follow-up data make it difficult to draw from
this report any other conclusion than the good cost-
effectiveness of supervised exercise programs when
compared with currently available drug therapy in
this group of patients. The costs of care for patients
with claudication and conservative (medical) treat-
ment were estimated from a cohort study of 300
patients.> Out of these, one third eventually
required an invasive diagnostic or therapeutic pro-
cedure. The total health care costs during the 2-year
follow-up period were roughly $6,000 (Euro 5,580),
three quarters of which was accounted for by hospi-
tal costs.
A report on cost data drawn from two national data-
bases in France gave an estimate of health care costs
(non-health care costs were not considered) for
patients with IC in 1992,4 The average hospital costs
estimated from the charges to Social Security were
$2,345 (Euro 2,181) per patient. When considering
patients with ambulatory treatment only, the costs
were $1,100 (Euro 1,023) per patient, with 75% of this
cost attributable to drug prescriptions. Other cost
items included consultations (20% of the total costs),
follow-up tests, and hydrotherapy.
Critical Issue 17: Costs in relation to measure of
effectiveness
There is a need to relate the costs of treating
patients with intermittent cIaudicant to a valid
measure of effectiveness and for this to be gauged
over time.
It appears that supervised exercise programs yield
good results on walking distance, unlike most drugs,
although the overall volume of drug prescriptions in
these patients tends to be high. The ambulatory costs,
however, appear to be low by comparison with the
costs incurred by patients with IC when hospitalisa-
tion is required.s A cost-effectiveness analysis showed
that, compared with exercise, treatment strategies that
included angioplasty or both angioplasty and bypass
surgery improved quality-adjusted life expectancye
However, the incremental cost-effectiveness ratios
were very high: $37,000 to 82,000 (Euro 34,410-76,260)
per QALY gained for strategies that included PTA and
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$202,000 to 779,000 (Euro 187,860-724,470) per QALY
gained for strategies that included both PTA and
bypass surgery. In patients with a history of CAD, a
noninterventional (ie, exercise only) strategy yielded
the highest quality-adjusted life expectancy at the low-
est lifetime costs.s
The costs of stent placement and PTA for iliac artery
occlusive disease were documented by the Dutch Iliac
Stent Trial Study Croup." Compared with primary
stent pl acement, angioplasty with selective stent
placement yielded equivalent complication rates,
patency results, and quality-of-life outcomes and was
cost saving. The health care costs of primary stent
were $3,786 (Euro 3,521) and increased to $3,990 (Euro
3,711) when non-health care costs were added. For
selective stent placement, these costs were, respective-
ly, $2,829 (Euro 2,631) and $3,033 (Euro 2,821).
Compared with angioplasty alone, which cost $2,139
(Euro 1,989) ($2,343 with non-health care costs),
angioplasty with selective stent placement was more
expensive but yielded higher patency results and
quality-adjusted life expectancy, and under varying
assumptions had an incremental cost-effectiveness
ratio of less than $20,000 (Euro 18,600) per QALY
gained.
Critical Issue 18: Comparison of relative cost-effec-
tiveness between various types of treatment
There is a need for future studies to compare the
relative cost-effectiveness over time between vari-
ous types of treatment: exercise programs, pharma-
cotherapy, other noninvasive therapy, and endovas-
cular or surgical intervention.
85.1.3
The Cost-effectiveness of Antiplatelet Therapy in
Intermittent Claudication
Based on current evidence, treating patients with PAD
with antiplatelet drugs appears to be effective in
reducing the risk of coronary and cerebrovascular
events" in maintaining arterial and graft patency 9.10
and in slowing progression of disease.t' From a cost-
effectiveness point of view, antiplatelet therapy is
inexpensive ($30 per year for aspirin medication). In
general, it is well accepted that all patients with PAD,
including those with IC, should be considered for
treatment with low-dose aspirin to reduce the risk of
cardiovascular morbidity and mortality (see
Recommendation 28, p S71).
The Antiplatelet Trialists' Collaboration showed a
nonsignificant reduction in vascular events (vascular
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death, MI, stroke) with antiplatelet therapy in patients
with IC of 10%, versus 12% in approximately 3,300
patients (Table 30).8 Taking into account that this rep-
resents a mean of 26 months' scheduled antiplatelet
therapy, we estimated the absolute benefit to be 9
events avoided per 1,000 person-years (PYs) of treat-
ment. The risk reduction among those with claudica-
tion is thus in the same order of magnitude as the risk
reduction with secondary prevention in patients with
a prior MI, prior stroke or transient ischaemic attack
(TIA), or other high-risk groups. The risk reduction
among those with claudication was, however, far less
than the risk reduction with secondary prevention in
patients with an acute MI (Table 30).
Although the risk reduction among those with IC
was nonsignificant, results among patients with PAD
were pooled with the results from similar high-risk
groups, excluding acute MI and prior MI, stroke, or
TIA. The pooled results showed a significant risk
reduction of 7% versus 9%, and no significant hetero-
geneity could be shown across the subgroups.
Excluding unstable angina from the pooled results,
there still remained a significant risk reduction of 6%
versus 8% and an absolute benefit of 20 events avoid-
ed per 1,000 PYs of treatment.
The largest prospective randomised trial in patients
with PAD regarding antiplatelet therapy was the
CAPRIE Trial. 12 This trial enrolled over 19,000
patients, with over 6,000 having the primary diagnosis
of PAD. This was confirmed by symptoms of claudi-
cation with a reduced ABPI, or prior vascular surgery.
Althogh the overall CAPRIE results were positive,
showing a statistically favourable benefit of clopido-
grel over aspirin in preventing cardiovascular events,
the PAD subgroup showed the greatest benefit. Thus,
this study provides additional information regarding
the importance of using antiplatelet therapies in
patients with cardiovascular disease. Patients with
PAD should all receive antiplatelet therapy to prevent
the risk of MI, stroke, and vascular death. The data
from the CAPRIE Trial (Table 31) suggest a clinically
and statistically significant better risk reduction with
clopidogrel than with aspirin in patients with PAD.
The current evidence suggests that antiplatelet ther-
apy in patients with IC, with the goal of reducing the
risk of coronary and cerebrovascular events, is compa-
rable to secondary prevention in those with a prior MI,
stroke, or transient ischaemic attack (TIA).Because sec-
ondary prevention in patients with a prior MI, stroke,
or TIA is considered cost-effective, and given the pos-
sible additional benefit of reducing the risk of vascular
occlusion and progression of disease, antiplatelet ther-
apy (with low-dose enteric-coated aspirin and possi-
bly clopidogrel in those who cannot tolerate aspirin)
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Benefit
Mean Antiplatelet therapy Control Observed- Benefit per
Patient Trials scheduled expected per 1,000
group n antiplRx' events n risk (%) events n risk (%) stratified Var 1,000 PYs
PriorMI 11 27 1,331 9,877 13.5 1,693 9,914 17.1 -158.5 561.6 32 14
AcuteMI 9 1 992 9,388 10.6 1,348 9,385 14.4 -177.9 510.3 38 455
Prior stroke/ 18 33 1,076 5,837 18.4 1,301 5,870 22.2 -98.5 386.5 34 12
TIA
Other high 10-l 16 784 11,434 6.9 1,038 11,542 9.2 -134 332.5 23 17
risk
Claudication 22 26+ 160 1,646 9.7 193 1,649 11.8 -15.7 63.6 19 9
Low risk 3 62 652 14,608 4.5 708 14,60-l 4.8 -28.5 273.5 4 0.8
Abbreviation: PY,patient years.
'From Figure 3.8
t Weighted mean estimated from Appendix,s
Table 31. Summary of results from the CArRIE trial 12
C1opidogrel Aspirin Relative risk reduction
Patient group n event rate (%) event rate (%) (95% confidence interval)
Stroke 6,431 7.15 7.71 7.3% (-5.7%-18.7%)
Myocardial infarction 6,302 5.03 4.84 -3.7% (-22.10/0-12.0%)
Peripheral arterial disease 6,452 3.71 4.86 23.8% (8.9°/0- 36.2%)
appears cost-effective in patients with intermittent
claudication (see also Recommendation 28, p 571).
85.1.4
The Cost-effectiveness of Lipid Control in Intermittent
Claudication
Patients with intermittent claudication present an
increased risk for acute MI and stroke.P''!
Cardiovascular event rates are close to those of
patients who have suffered a recent MI (see A 2.5.3,
Summary: Fate of the Claudicant, p 518). Therefore,
lipid-lowering interventions should be analysed. as
secondary prevention interventions. Secondary pre-
vention using lovastatin in men with pretreatment
cholesterol levels between 250 and 299 mg/dL (6.5-7.7
mmol/L) was shown to be very expensive in prevent-
ing CAD.IS Only in those with at least three risk fac-
tors, and in those with at least two risk factors includ-
ing an excessively high cholesterol level (above 300
mg/dL), was primary prevention cost-effective in pre-
venting CAD. Secondary prevention using lovastatin
was demonstrated to be cost-effective in most situa-
tions, with acceptable incremental cost-effectiveness
ratios depending on age, pretreatment cholesterol lev-
els, and dosage.
A related, more recent analysis demonstrated that
the projected gain in quality-adjusted life-years with
secondary prevention according to the NCEP guide-
lines was 0.05 to 0.08/PY of treatment." The incre-
mental gain with primary prevention in high-risk
groups (compared with secondary prevention only)
was 0.014 to 0.015 QALYs/PY of treatment. Adding
primary prevention in moderate-risk groups added
only 0.008 to 0.009 QALYs/PY of treatment.
Prevention in this context is primary in the sense that
these patients have not had a prior MI or prior
stroke/TIA-that is, no known coronary or carotid
disease. However, it can be considered secondary in
the sense that these patients are known to have athero-
sclerotic disease.
To put these numbers in perspective, treating
patients for 30 years would yield a gain of 1.5 to 2.4
QALYs with secondary prevention and 0.24 to 0.45
QALYs with primary prevention. By comparison,
revascularisation for CAD yields between 0.9 and 1.5
QALYs,!7 Summarising the numbers above, the incre-
mental cost-effectiveness ratio of primary prevention
will be roughly 5 to 10 times that of secondary pre-
vention. In patients with IC, the cost-effectiveness of
secondary prevention with a statin is approximately
$40,000 per QALY gained (Euro 37,200), which is cost-
effective in the current health care environrnent.ts
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CLINICAL TRIAL ISSUES IN INTERMITTENT
CLAUDICATION
86.1
Introduction
B 6.1.1
Scope of Section
Most clinical trials in IC relate to the use of pharma-
cological agents. Surgical treatment is rarely indicat-
ed in patients with IC and has not been the subject of
comparative studies. A number of trials of exercise
programs have been reported and are discussed in
Basic Treatment (B 4.1.2, P 568). Some of the prob-
lems specific to these trials are discussed in that sec-
tion and largely centre around the problem of blind-
ing the patient and the observer as well as the prob-
lem of a suitable comparator treatment. Two compar-
ative studies of angioplasty and exercise programs
are also discussed in that section.
This chapter deals predominantly with the issues
surrounding trials of pharmacological treatment. It
does not attempt to be exhaustive but focuses on
selected controversial aspects of trial methodology.
Until recently, there have been remarkably few good
studies looking at the methodology of such trials; for
instance, it is only very recently that the relative mer-
its of constant versus graded treadmill exercise has
been investigated (see B 6.4.1, Constant Versus
Graded Treadmill Protocol, p 5112). Fundamental
questions such as the reason for the day-to-day vari-
ability in treadmill walking distance, whether such
variability is specific to a particular patient or
whether patients with a very short claudication dis-
tance behave fundamentally differently from those
with a long claudication distance, have not been fully
investigated. There is therefore very little basis for
making firm recommendations based on scientific
evidence. The Recommendations that follow are
based largely on what is perceived to be the current
best advice, rather than firm evidence. The
Recommendations therefore could equally well be
labelled as Critical Issues.
B 6.1.2
Existing Guidelines for Clinical Trials in Intermittent
Claudication
Over the years, a number of guidelines for clinical tri-
als of pharmacotherapy in lC have been proposed by
individual countries in Europe or by the new
